期刊文献+

CPP Tat_(49-57)促进外源CTL表位进入MHC-Ⅰ类抗原呈递途径的机制研究 被引量:4

Mechanisms of the MHC class I-associated presentation of exogenous CTL epitope fused with cell-penetrating peptides
暂未订购
导出
摘要 目的研究穿膜肽(cell-penetrating peptides,CPP)促进外源CTL表位进入抗原呈递细胞(antigen-presenting cell,APC)内MHC-Ⅰ类抗原呈递途径的效应及呈递机制。方法应用多肽固相合成技术,将源于HIV-Tat的穿膜序列Tat49-57连接在H-2Kb限制性CTL表位OVA257-264的氨基端形成融合肽即Tat49-57-CTL257-264,同时合成该表位和氨基端自然延伸的对照肽NH2 extended-OVA257-264。采用流式细胞仪(FACS)分析技术,检测APC对各肽的MHC-Ⅰ类抗原呈递动力学,并进行MHC-Ⅰ类抗原呈递阻断和TAP依赖性实验。结果在所测时间点,APC对于Tat49-57-CTL257-264的呈递强度均明显高于NH2 extended-OVA257-264;氨基肽酶抑制剂Bestatin可部分抑制APC对于Tat49-57-CTL257-264的MHC-Ⅰ类抗原呈递,而蛋白酶体抑制剂Lactacystin则无抑制效应;Tat49-57-OVA257-264可被TAP缺陷细胞RMA-S内MHC-Ⅰ类分子有效呈递,其呈递强度远超过RMA-S细胞对NH2extended-OVA257-264的呈递。此外,RMAS固定后则丧失对Tat49-57-OVA257-264和NH2 extended-OVA257-264的MHC-Ⅰ类限制性呈递能力,但其表面的“空”MHC-Ⅰ类分子仍可呈递单纯表位肽OVA257-264。结论CPP Tat49-57可有效促进与之融合的CTL表位肽被细胞内MHC-Ⅰ类分子提呈,表现为动力学显著增强,且该过程表现为蛋白酶体/TAP非依赖、氨基肽酶依赖。 Objective To study the time-dependent kinesics and mechanisms of MHC class Ⅰ antigen presentation of CTL epitopes peptides fused with cell-penetrating peptides (CPP). Methods Peptides termed Tat49-57-OVA257-264, which contains a HIV Tat-derived CPP (Tat49-57) and a H-2K^b-restricted CTL epitope (OVA257-264), were synthesized with solid-phase synthesis method. An N-termini extended epitope (NH2 extended-OVA257-264) and an epitope peptide (OVA257-264) were used as controls. Flow cytometric analysis was used to detect the time-dependent kinetics of MHC class Ⅰ -associated antigen presentation by APC fed with these peptides. In addition, inhibition and TAP-dependence of MHC class Ⅰ-associated presentation were also explored. Results Tat49-57-OVA257-264 could be more efficiently processed for MHC class Ⅰ molecules presentation than control peptides. Bestatin (a kind of aminopeptidase inhibitor), not Lactacystin (a kind of proteasome inhibitor), could partly impair MHC class Ⅰ -associated presentation of Tat49-57-OVA257-264. MHC class Ⅰ -associated presentation of Tat49-57-OVA257-264 was much stronger than that of NH2 extended-OVA257-264 in RMA-S, a TAP-deficient cell. Except the minimal peptide, both two extended peptides failed to be presented by surface class I molecules in fixed cells. Conclusion CPP Tat49-57 can effectively promote the MHC class Ⅰ -associated antigen presentation of CTL epitope, and this course is TAP/proteasome independent as well as aminopeptidase dependent, and need intracellular processing.
出处 《免疫学杂志》 CAS CSCD 北大核心 2006年第3期247-251,共5页 Immunological Journal
基金 国家自然科学基金资助项目(30371329 30400437)
关键词 穿膜肽 Tat49-57 CTL表位 MHC-Ⅰ类抗原呈递 Cell-penetrating peptides Tat49-57 CTL epitope MHC class Ⅰ -associated presentation
  • 相关文献

参考文献8

  • 1王莉,吴玉章.穿膜肽研究展望[J].免疫学杂志,2001,17(z1):12-16. 被引量:2
  • 2王莉,吴玉章,石统东,贾正才,周伟,邹丽云.穿膜肽HIV-Tat_(49-57)和CTL表位融合多肽疫苗的初步免疫学效应研究[J].第三军医大学学报,2002,24(10):1159-1161. 被引量:3
  • 3王莉,吴玉章,林治华,石统东,周伟,贾正才,邹丽云.穿膜序列对MHC-Ⅰ类限制性CTL表位呈递影响的研究[J].第二军医大学学报,2002,23(10):1106-1108. 被引量:3
  • 4Porgador A, Yewdell JW, Deng Y, et al. Localization,quantitation, and in situ detection of specific peptide-MHC class Ⅰ complexes using a monoclonal antibody [ J ]. Immunity, 1997, 6 (6) : 715- 726.
  • 5Saric T, Beninga J, Graef CI, et al. Major histocompatibility complex class Ⅰ-presented antigenic peptides are degraded in cytosolic extracts primarily by thimet oligopeptidase [J]. J Biol Chem, 2001, 276 (39) : 36 474 - 36 481.
  • 6Schwarz K, de Giuli R, Schmidtke G, et al. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up-or down-regulate antigen presentation at nontoxic doses [J]. J Immunol, 2000, 164 (12): 6 147-6 157.
  • 7Mo XY, Cascio P, Lemerise K, et al. Distinct proteolytic processes generate the C and N termini of MHC class Ⅰ-binding peptides [J]. J Immunol, 1999, 163 (11): 5 851 -5 859.
  • 8倪兵.蛋白酶体与MHC-Ⅰ类抗原的加工呈递[J].免疫学杂志,2001,17(5):391-395. 被引量:9

二级参考文献34

  • 1王莉,吴玉章.穿膜肽研究展望[J].免疫学杂志,2001,17(z1):12-16. 被引量:2
  • 2[1]Joliot A, Pernelle C, Deagostini Bazin H, et al. Antennapedia homeobox peptide regulates neural morphogenesis [J]. Proc Natl Acad Sci USA, 1991,88(5): 1 864- 1 868.
  • 3[2]Schwarze SR, Ho A, Vocero Akbani A, et al. In vivo protein transduction: delivery of a biologically active protein into the mouse [J] .Science,1999,285(5 433): 1 569- 1 572.
  • 4[3]Schwarze SR, Dowdy SF. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA[J].Trends Pharmacol Sci, 2000, 21(2): 45-48.
  • 5[4]Derossi D, Joliot AH, Chnssaing G, et al.The third helix of the Antennapedia homeodomain translocates through biological membranes[J]. J Biol Chem, 1994,269(14): 10 444-10 450.
  • 6[5]Elliott G, O' Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein [J]. Cell, 1997,88(2): 223 - 233.
  • 7[6]Phelan A, Elliott G, O' Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22 [J]. Nat Biotechnol, 1998,16(5): 440 - 443.
  • 8[7]Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells[ J ]. Proc Natl Aead Sci USA,1994, 91(2): 664 - 668.
  • 9[8]Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus[J]. J Biol Chem,1997,272(25): 16 010- 16 017.
  • 10[9]Nagahara H, Vocero Akbani AM, Snyder EL, et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kipl induces cell migration [J]. Nat Med,1998,4(12):1 449-1 445.

共引文献12

同被引文献64

引证文献4

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部